Avalon GloboCare Subsidiary GenExosome Expands Operations into the United States

Biotech Investing

Avalon GloboCare (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that its majority-owned subsidiary, GenExosome Technologies (GenExosome), has formally launched its U.S. operations, with plans to market and distribute its proprietary Exosome Isolation Systems from its new headquarters in Ohio. The Company also announced plans to develop proprietary diagnostic and therapeutic products leveraging its exosome …

Avalon GloboCare (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that its majority-owned subsidiary, GenExosome Technologies (GenExosome), has formally launched its U.S. operations, with plans to market and distribute its proprietary Exosome Isolation Systems from its new headquarters in Ohio. The Company also announced plans to develop proprietary diagnostic and therapeutic products leveraging its exosome technology. The Company has already begun hiring personnel for marketing and customer fulfilment.

As quoted in the press release:

Yu Zhou, M.D., Ph.D, Co-CEO of GenExosome stated, “In recent years, the rapid development of the exosome market has attracted attention from scientists and clinicians. However, the clinical application of exosomes is hampered by a lack of optimal methods for isolation and purification of high quality exosomes. When compared to conventional exosome isolation methods, our novel exosome isolation system provides an efficient and robust method of obtaining high-purity exosome population devoid of contamination with other similar size particles and proteins. We are excited to launch our operations in the Unites States.”

Click here to read the full press release.

The Conversation (0)
×